Jefferies Maintains Buy Rating on Rhythm Pharmaceuticals (RYTM), Sets $80 Price Target
In a report released on June 4, Dennis Ding from Jefferies maintained a Buy rating on Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) with a price target of $80.00. The analyst based the rating on the company's strategic developments and promising pipeline.
One of the primary reasons behind the rating was the anticipated Phase II data for the oral treatment for hypothalamic obesity (HO). It is expected to deliver notable BMI reduction and has been de-risked, thereby extending the potential of the franchise beyond the current expiration dates.
A scientist conducting research in a laboratory, studying a Petri dish with advanced biopharmaceuticals.
The analyst stated that management is confident in the weekly subcutaneous (subQ) treatment, which closely aligns with the previously approved setmelanotide, and thus further adds to the positive outlook for Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM).
According to Ding, the setmelanotide Phase II open-label trial for Prader-Willi Syndrome can also pave the way for a significant opportunity if successful, even after its previous challenges. Management is focusing on patient starts instead of the immediate revenue post-launch, and this strategy supports the long-term growth prospects, according to the analyst.
Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) is a commercial-stage biopharmaceutical company that develops and commercializes therapeutics for the treatment of rare diseases. Its product pipeline includes IMCIVREE (setmelanotide), a precision medicine that treats hyperphagia and severe obesity caused by rare melanocortin-4 receptor (MC4R) diseases. The company also has other programs, including a preclinical suite of investigational candidates to treat congenital hyperinsulinism and a clinical development program for setmelanotide in other rare MC4R pathway diseases.
While we acknowledge the potential of RYTM as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.
READ NEXT: and .
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 hours ago
- Yahoo
J.M. Smucker Reinforces Dividend Strength as Analyst Confidence Remains High
The J. M. Smucker Company (NYSE:SJM) is one of the 10 best dividend stocks according to Jim Cramer. Jefferies reiterated a Buy rating for the stocks, maintaining the earlier adjusted price target of $115. A wholesaler distributing peanut butter, fruit spreads and specialty spreads to a retailer. Ohio-based company, The J. M. Smucker Company (NYSE:SJM) is among the largest food and beverage manufacturers, primarily operating in North America. The company's product portfolio includes coffee, pet food, peanut butter, fruit spreads, baking mixes, and frozen handheld items, among others. Operating through various brands like Folgers, Dunkin', Café Bustelo, Jif, and Smucker's, the company has enhanced its global presence. On June 11, 2025, Jefferies upgraded The J. M. Smucker Company (NYSE:SJM)'s rating from Hold to Buy. Though the rating went up, the price target was adjusted from $118.00 to $115.00, reaching a 2.54% decrease. On June 12, 2025, Director Tarang Amin purchased 1,050 shares of The J. M. Smucker Company (NYSE:SJM). Acquired at an average price of $96.09 each, the value of the total shares purchased by Amin stands at $100,894.50. The move was considered bold since, in addition to Jefferies, other investment managers like Stifel and Wells Fargo also lowered their price target on the company. On June 14, 2025, Jefferies maintained their Buy rating on the stock without any changes to the price target, earlier iterated as $115. For investors interested in the company's dividend payments, The J. M. Smucker Company (NYSE:SJM)'s dividend yield stands at 4.44% and is backed by a payout ratio of 86.06% and 28 years of consecutive growth. While we acknowledge the potential of SJM as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: andDisclosure. None.
Yahoo
5 hours ago
- Yahoo
Why Applied Optoelectronics Stock Skyrocketed Today
Applied Optoelectronics stock rocketed higher Friday thanks to new financing disclosures from the company. The tech specialist announced that one of its subsidiaries had taken on a new loan that was used to pay a previously existing loan. News of the refinancing move follows an announcement that the company recently made a major product shipment to a hyperscaler customer. 10 stocks we like better than Applied Optoelectronics › Applied Optoelectronics (NASDAQ: AAOI) stock soared higher again in Friday's trading. The tech specialist's share price rose 18.6% in the daily session despite a 0.2% decline for the S&P 500 (SNPINDEX: ^GSPC) and a 0.5% fall for the Nasdaq Composite (NASDAQINDEX: ^IXIC). Applied Optoelectronics' valuation surged today thanks to news that one of the company's subsidiaries had reworked previously existing debt agreements. The stock climbed roughly 39% over the last week of trading. After the market closed on Wednesday, Applied Optoelectronics submitted a filing to the Securities and Exchange Commission (SEC) revealing two significant financing changes for its Global Technology subsidiary. Because the stock market was closed for the Juneteenth federal holiday on Thursday, the investor reaction to the new disclosures was pushed into today's trading. As per the filing with the SEC, Applied Optoelectronics' Global Technology has entered into a one-year credit agreement with China Construction Bank totaling 96.8 million Chinese renminbi -- which works out to roughly US$111.55 million based on the current exchange rate. Applied Optoelectronics said that the funding from the new agreement had been used to pay back other outstanding loans with Shanghai Pudong Development Bank. Despite this week's rally, Applied Optoelectronics stock is still down roughly 36% across the year due to uneven business performance and concerns about the company's financing. On the other hand, the company has recently announced significant shipments for its high-speed data center transceivers for a major data center customer. Along with some indications that the company could see an increase in demand powered by artificial intelligence (AI) initiatives from cloud hyperscaler customers, the recently announced financing moves suggest that the company has a found a near-term solution to some of its financing challenges. Before you buy stock in Applied Optoelectronics, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Applied Optoelectronics wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $659,171!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $891,722!* Now, it's worth noting Stock Advisor's total average return is 995% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 9, 2025 Keith Noonan has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why Applied Optoelectronics Stock Skyrocketed Today was originally published by The Motley Fool
Yahoo
8 hours ago
- Yahoo
Vertex (VRTX) Stock PT Lowered to $420 on slower Alyftrek Uptake
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the 10 biotech stocks screaming a buy. On June 17, RBC Capital reiterated a Sector Perform rating on the stock but cut the price target to $420 from $423. The adjustment is in response to the company confirming gradual patient conversion from Trikafta to the company's next-generation cystic fibrosis treatment, Alyftrek. A research team in lab coats testing a new ImmunoPhage platform in a modern biotechnology lab. RBC Capital remains concerned about the gradual conversion compared to consensus expectations. Consequently, it has warned it could affect the company's operating margins by up to 2%. Nevertheless, the research firm insists that the company's cystic fibrosis franchise remains well-insulated from sector headwinds. However, RBC Capital has reiterated that Vertex could require stronger execution to adopt Alyftrek to justify the current valuation in the market. Consequently, its reduced price target reflects lower year Alyftrek conversion rates. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is a global biotechnology company that develops and commercializes therapies for serious diseases. They are known for their work in cystic fibrosis (CF) and are expanding into other areas like cell and genetic therapies. While we acknowledge the potential of VRTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 13 Best Software Stocks to Buy Now and 11 Must-Buy AI Stocks Analysts Are Betting On. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
